Gemstone Biotherapeutics, a Baltimore company developing treatments to promote wound healing, has raised $2.45 million in a seed round of investment, company officials said.
The company plans to use the money to further test its technologies and pursue regulatory review and clinical trials. It is developing biosynthetic “scaffold” technology that has shown in animal tests it can help skin regenerate and prevent scarring when applied to burn wounds.
{iframe}http://www.baltimoresun.com/business/bs-bz-gemstone-biotherapeutics-20150605-story.html{/iframe}